Henan Lingrui Pharmaceutical Co., Ltd.

SHSE:600285 Stock Report

Market Cap: CN¥14.4b

Henan Lingrui Pharmaceutical Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Wei Xiong

Chief executive officer

CN¥1.8m

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership0.6%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 04
Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Held Back By Insufficient Growth Even After Shares Climb 27%

Should You Be Adding Henan Lingrui Pharmaceutical (SHSE:600285) To Your Watchlist Today?

Feb 29
Should You Be Adding Henan Lingrui Pharmaceutical (SHSE:600285) To Your Watchlist Today?

CEO

Wei Xiong (37 yo)

no data

Tenure

CN¥1,772,800

Compensation

Mr. Wei Xiong serves as General Manager and Director at Henan Lingrui Pharmaceutical Co. Ltd. and served as its Chairman and Managing Director.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.